AI Medical Device Security has moved from a technical control set into a formal submission and quality-system issue for connected medical technology. On February 3, 2026, the FDA issued final guidance titled Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, updating expectations for cyber device design, labeling, documentation, and postmarket resilience through the HHS guidance portal.
The change matters beyond hospital IT departments. Sports medicine clinics, rehabilitation providers, athlete monitoring programs, and performance labs may use software-enabled devices that connect to networks, receive updates, or process sensitive health data. If a product falls within the statutory definition of a cyber device, the security file is no longer a secondary engineering appendix. It becomes part of how the sponsor supports safety, effectiveness, and postmarket maintenance.
The rules also intersect with AI-enabled device software functions, known in FDA materials as AI-DSFs. The FDA released draft guidance on January 6, 2025 for lifecycle management and marketing submissions for AI-enabled device software functions, including transparency, performance monitoring, bias, and update strategies. On August 18, 2025, the agency issued final guidance on predetermined change control plans for AI-enabled device software functions, allowing sponsors to describe planned software changes before market release. Those AI-specific policies sit next to the cybersecurity guidance rather than replacing it.
AI Medical Device Security Moves Into QMS
What Changed On February 3, 2026
The February 3, 2026 final guidance placed cybersecurity inside the quality-management discussion for connected devices. That matters because AI software tends to change through data updates, model monitoring, bug fixes, and feature revisions. A sponsor cannot treat security as a one-time penetration test if the device is expected to remain connected, patched, and monitored after clearance or approval.
The guidance emphasizes that cybersecurity is part of device safety and effectiveness. It also states that controls should account for intended and actual use environments. In practical terms, a system designed for a controlled hospital network may face different operational risk if deployed in outpatient sports rehabilitation, a university training facility, or a remote monitoring workflow. The supported fact is not that every such deployment creates the same risk. The supported point is that the assessed environment matters.
Why AI Medical Device Security Now Includes SBOMs
Section 524B of the Federal Food, Drug, and Cosmetic Act became effective on March 29, 2023. It requires manufacturers submitting 510(k), PMA, De Novo, PDP, or HDE applications for a cyber device to include cybersecurity information under section 524B(b). The FDA defines a cyber device as one that includes sponsor-validated, installed, or authorized software; has internet connectivity; and contains technological features that could be vulnerable to cybersecurity threats, according to the FDA cybersecurity FAQ.
The required elements include a plan to monitor, identify, and address postmarket vulnerabilities and exploits, including coordinated vulnerability disclosure. They also include processes for cybersecure design, development, maintenance, updates, and patches. A Software Bill of Materials must list commercial, open-source, and off-the-shelf software components.
For AI Medical Device Security teams, the SBOM requirement is especially important because AI-enabled systems often depend on layered software stacks. The requirement does not, by itself, prove that every component is safe. It does create a traceable inventory that can support vulnerability response, update planning, supplier review, and submission consistency.
Compliance Implications For AI-Enabled Devices
Postmarket Plans Are No Longer Side Documents
The compliance effect is direct. A manufacturer must show how it will monitor and address vulnerabilities after the device reaches users. This includes coordinated vulnerability disclosure and patch processes. For AI-enabled devices, the postmarket plan may need to align security maintenance with model performance monitoring and update governance.
The guidance also states that failure to comply with section 524B(b)(2), which addresses reasonable assurance of cybersecurity across the device and related systems, is a prohibited act under section 301(q) of the FD&C Act. That raises the cost of treating cybersecurity as informal engineering work. Documentation quality, change history, risk analysis, and patch readiness can affect both regulatory position and operational trust.
This does not mean every AI-enabled product is regulated in the same way. The statutory cyber device definition still controls whether section 524B applies. The FDA’s AI software policies also depend on the device function and submission pathway. A related analysis of postmarket monitoring and SBOM discipline reaches a similar operational point: compliance is shifting toward maintained evidence rather than static launch documentation.
Predetermined Change Plans And Model Updates
The August 18, 2025 final guidance on predetermined change control plans is relevant because AI-enabled device software functions may need planned changes after marketing authorization. A PCCP can describe the types of modifications expected and the method used to control them. This is not a blank permission slip for uncontrolled model changes. It is a way to frame anticipated updates within a reviewed plan.
Security and AI governance can conflict if they are managed by separate teams. A security patch might affect software dependencies. A model update might change data handling or system behavior. A performance-monitoring process might introduce new logging obligations. Manufacturers need change-control procedures that connect these events rather than recording them in separate silos.
Cost pressure will be uneven. Large device makers may already operate formal vulnerability intake, SBOM management, and update pipelines. Smaller vendors serving sports clinics or rehabilitation practices may face heavier relative burden, especially if their software stack includes open-source components and third-party cloud services. In related developments beyond clinical systems, clear data practices at stampsinclass.com, a related site in the same network, highlight the importance of software stewardship.
Generative AI Devices Remain A Draft Policy Question
A Two-Axis Risk Concept
On August 18, 2026, the FDA opened public docket FDA-2026-N-7874 with a discussion paper on generative AI-enabled medical devices. The agency requested feedback by October 19, 2026. As of September 10, 2026, that work remained under discussion and was not final policy.
The discussion paper considers a risk-based, two-axis framework. One axis looks at how autonomous the device is. The other looks at how severe the consequence could be if the device output is wrong. That concept is technically sensible because not all generative outputs carry the same clinical risk. A low-autonomy documentation assistant differs from a system that produces a high-impact recommendation with limited human review.
The unresolved issue is how sponsors should validate generative behavior that may vary with prompts, context, and underlying model updates. The research record supports the fact that the FDA is seeking feedback on risk assessment, premarket evaluation, postmarket monitoring, competency assessment, and foundation-model considerations. It does not support a claim that the FDA has already settled a final generative AI framework.
Security Risks Are Maintenance Risks
Generative AI adds security questions that fit within existing medical-device cybersecurity concepts. The defensive concerns include dependency tracking, update control, access management, logging, monitoring for abnormal behavior, and procedures for responding to newly discovered vulnerabilities. The FDA materials cited here do not provide product-specific technical controls for every AI architecture. They point manufacturers toward documented, risk-scaled processes.
That distinction is important for sports technology vendors that may sit near the edge of regulated medical use. A performance analytics tool is not automatically a medical device. A connected AI-enabled function used for diagnosis, treatment, or regulated clinical decision support may face different obligations. The technical boundary depends on the product’s intended use, claims, software function, connectivity, and vulnerability profile.
AI Medical Device Security After February 2026
Who Carries The Operational Burden
The operational burden falls first on manufacturers, but it reaches suppliers, clinical users, and service partners. Sponsors need credible inventories, documented secure development processes, patch plans, vulnerability monitoring, and postmarket response procedures. Suppliers may need to provide component data. Clinical users may need to maintain update channels and avoid unsupported configurations that weaken the manufacturer’s risk assumptions.
AI Medical Device Security now depends on evidence that can be maintained after clearance or approval. The February 2026 guidance did not create a universal checklist that guarantees safety. It did make cybersecurity evidence more central to premarket submissions and postmarket accountability. For AI-enabled medical devices, the main compliance question is no longer whether security has been considered. It is whether the sponsor can show how security, model maintenance, software change control, and real-world operating conditions are managed over the device lifecycle.
